Frankfurt - Delayed Quote EUR

Immutep Limited (YP1A.F)

1.5600
-0.0600
(-3.70%)
At close: May 9 at 8:08:39 AM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
0
0
0
170.3690
0
Operating Expense
46,557.4620
46,557.4620
41,431.3050
34,007.7070
19,656.0790
Operating Income
-46,557.4620
-46,557.4620
-41,431.3050
-33,837.3380
-19,656.0790
Net Non Operating Interest Income Expense
3,852.1630
3,852.1630
918.5980
132.0900
95.5020
Other Income Expense
-11.3260
-11.3260
616.3590
1,494.4560
-10,342.0140
Pretax Income
-42,716.6250
-42,716.6250
-39,896.3480
-32,210.7920
-29,902.5910
Tax Provision
0
0
0
0.0340
0.0330
Net Income Common Stockholders
-42,716.6250
-42,716.6250
-39,896.3480
-32,210.8260
-29,902.6240
Diluted NI Available to Com Stockholders
-42,716.6250
-42,716.6250
-39,896.3480
-32,210.8260
-29,902.6240
Basic EPS
-0.36
--
-0.45
-0.38
-0.49
Diluted EPS
-0.36
--
-0.45
-0.38
-0.49
Basic Average Shares
120,106.1930
--
89,239.9810
84,896.8070
60,987.6950
Diluted Average Shares
120,106.1930
--
89,239.9810
84,896.8070
60,987.6950
Total Expenses
46,557.4620
46,557.4620
41,431.3050
34,007.7070
19,656.0790
Net Income from Continuing & Discontinued Operation
-42,716.6250
-42,716.6250
-39,896.3480
-32,210.8260
-29,902.6240
Normalized Income
-42,830.0830
-42,830.0830
-40,651.7550
-33,484.2604
-23,483.5855
Interest Income
3,882.7570
3,882.7570
938.9990
224.5200
105.3270
Interest Expense
30.5940
30.5940
20.4010
92.4300
9.8250
Net Interest Income
3,852.1630
3,852.1630
918.5980
132.0900
95.5020
EBIT
-42,686.0310
-42,686.0310
-39,875.9470
-32,118.3620
-29,892.7660
EBITDA
-42,686.0310
-42,686.0310
-39,875.9470
-32,118.3620
-29,892.7660
Reconciled Depreciation
2,261.8580
--
--
2,999.6134
--
Net Income from Continuing Operation Net Minority Interest
-42,716.6250
-42,716.6250
-39,896.3480
-32,210.8260
-29,902.6240
Total Unusual Items Excluding Goodwill
113.4580
113.4580
755.4070
1,819.1920
-9,170.0550
Total Unusual Items
113.4580
113.4580
755.4070
1,819.1920
-9,170.0550
Normalized EBITDA
-42,799.4890
-42,799.4890
-40,631.3540
-33,937.5540
-20,722.7110
Tax Rate for Calcs
0
0
0
0.0003
0.0003
Tax Effect of Unusual Items
0
0
0
545.7576
-2,751.0165
6/30/2021 - 6/5/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1CG.SG CRISPR Therapeutics AG
31.80
-1.85%
 
JSPR Jasper Therapeutics, Inc.
4.5200
+2.03%
 
BCAB BioAtla, Inc.
0.4298
-9.13%
 
LQDA Liquidia Corporation
15.26
-0.59%
 
VKTX Viking Therapeutics, Inc.
27.55
-1.08%
 
CRSP CRISPR Therapeutics AG
35.62
-1.44%